Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI57MF
|
|||
| Drug Name |
Nivatrotamab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | ||
| Company |
Memorial Sloan Kettering; Y-mAbs Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ganglioside GD2 (GD2) | Target Info | Inhibitor | [1] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [1] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Y-mAbs Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.